

EUROPEAN FEDERATION OF CLINICAL CHEMISTRY AND LABORATORY MEDICINE

EFLM General Meeting Mannheim (DE)

19 June 2018 – h. 16.00-19.00
Congress Center Rosengarten - Meeting room: Hall 3.7 Arnold Schönberg
(Rosengartenplatz 2, Mannheim)

<u>Chair</u>: M. Neumaier, EFLM President Minutes taken by Giuseppe Lippi, EFLM Secretary

MINUTES

1. Session - Executive Board Reports

1.1. Opening and welcome, M. Neumaier (MN), President

The EFLM President greeted the audience and welcomed delegates to the General Meeting (GM) in Mannheim and presented the agenda of the meeting.

1.2. Approval of the minutes of the previous GM and membership issues, G. Lippi (GL), EB Secretary

No matters arising from the minutes of the last GM in Athens, June 2017. Minutes were otherwise approved. Approval of all the points in the Agenda of the GM will be by acclamation except for points 1.2.1 and 1.2.2. Overall, 14 National Societies were present at the GM.

1.2.1.LABAC (National network of Accredited Medical Biology Laboratories / Réseau de Laboratoires de Biologie Medicale Accrédités): membership request as Affiliate Member

The EFLM Secretary, informed the GM audience that the current EFLM regulations encompasses that the quorum will be set at 50% + 1 vote of all valid votes expressed by National Representatives attending the GM (abstentions, blank or spoiled votes will not be counted). The EFLM Secretary then informed the audience that voting will take place by raising hand with the voting slip. The majority of the national societies present to the meeting voted in favour. LABAS otherwise approved as EFLM Affiliate Member.

1.2.2.Kazakhstan Public Association «Federation of Laboratory Medicine»: membership request as Affiliate Member

The EFLM Secretary reminded the voting procedure, as for above. The majority of the national societies present to the meeting voted in favour. Kazakhstan Public Association «Federation of Laboratory Medicine» otherwise approved as EFLM Affiliate Member.

1.3. President's report, M. Neumaier, President

Michael Neumaier (MN), EFLM President provided an overview on the current EFLM organization (EB, functional units), on recent EFLM activities since the last GM in Athens (including recent official publications, meetings, bursary programs, EFLMLabX, participation of EFLM EB members to national societies' meetings, agreement with Clinical Chemistry and Laboratory Medicine, EFLM EB meeting with IVD representatives, EuroLabNews), and also gave a brief overview on the

ongoing and future projects within the EFLM. No comments raised. The report was endorsed. Power point presentation with the report can be viewed and downloaded from EFLM's website.

1.4. EFLM Regional Representative in the IFCC Executive Board, S. Sandberg, Past-President

SS provided an overview on the new IFCC statute which encompasses the presence of one EFLM representative in the IFCC board and briefly explained how the representative is elected by the EFLM and gave an overview of the current composition of IFCC Regional Federation Representatives. Discussion raised on the mutual advantages for IFCC and EFLM of having a Regional Federation Representatives within the IFCC EB.

1.5. Treasurer's report, H. Storm (HS), Treasurer

HS, EFLM Treasurer, gave a report on the following:

- 1. Financial audit 2017
- 2. Balance sheet 2017
- 3. Internal budget 2018

Audit of the EFLM financial matters for 2017 had been done in accordance with GAAP (Generally Accepted Accountant principles) by the certified auditor. HS presented the Balance sheet for 2017 according to Belgian GAAP and invited EFLM NSs for its approval. GM approved the accounts unanimously (which constitutes the discharge for EB members and certification of the accounts). HS also presented the Internal Preliminary Budget 2018 and asked for its formal approval. EFLM GM approved the Internal Preliminary Budget unanimously.

2. Session 2 – EFLM Strategic Plan

2.1. Discussion/endorsement of the EFLM Strategic Plan 2018-19, M. Neumaier, President

MN emphasized that achieving better health and healthcare through Laboratory Medicine would only be possible with involvement of EFLM National Society Members and this is the reason why last September they were asked to participate in the survey concerning the level of satisfaction towards EFLM. The main aim of the survey was to assess collaboration, specifically by:

- understanding the needs of our National Societies;
- checking how National Societies see the relationships with EFLM;
- receiving suggestions on how to improve the relationship with EFLM.

Starting from these results and from the on-going items of the previous plan, the EB based the preliminary study to prepare the draft for the EFLM Strategic Plan 2018-2019. Compared to previous editions, it was considered important to have a Strategic Plan made for a 5-10 year horizon while maintaining shorter term 2-year action plans. A SWOT analysis (see below) was used by the Executive Board to identify the main goals (7) where to concentrate the strategic plan and the 2-year related actions (18).

	Helpful		Harmful
Internal	Strengths (S)		Weaknesses (W)
	1.	Scientific output of EFLM functional units	 Relationships with NSs
	2.	Scientific events	2. Relationships with Clinical
	3.	Expertise	Societies
	4.	Good communication tools	3. Inactive EFLM Functional
	5.	Opportunities for YSs	Units
			4. Heterogeneous
			5. Lack of knowledge how to
			handle complex data
External	Opportunities (O)		Threats (T)
	1.	EU funding	 MedTech Code
	2.	Educational needs of NSs / other	2. Not effective recognition of
		stakeholders	the Profession
	3.	European guidelines	3. Low communication with

- 4. Emerging technology
- 5. Emerging diseases
- 6. Collaboration with IVD
- 7. Standardization & harmonization
- 8. Demonstrate the added value of LM
- patients
- 4. Competing disciplines close LM
- 5. Direct-to-consumer testing
- Low resources

MN then presented the proposed draft of the EFLM Strategic Plan 2018-2022, with action plan 2018-2019.

According to the analysis, the following **Strategic Goals** were identified:

- Improve the recognition of the LM as a medical profession
- Address needs of EFLM NSs
- Acquire competencies in biomedical informatics for management of complex diagnostic data
- Strengthen the scientific output of EFLM
- Regulation of the Profession
- Increase external financial support
- Facilitate harmonization in Europe

After a short discussion the strategic plan was finally approved.

3. Session 3 – Reports from Committee Chairs

3.1. Report from the Science Committee, E. Kilpatrick (EK), C-S Chair

EK (C-S Chair) reported about the past and ongoing activities within the EFLM functional units. Power point presentation with the report can be viewed and downloaded from EFLM's website.

3.2. Report from the Profession Committee, G. Wieringa (GW), C-P Chair

GW (C-P Chair) reported about the past and ongoing activities within the EFLM functional units. Power point presentation with the report can be viewed and downloaded from EFLM's website.

3.3. Report from the Quality & Regulations Committee, W. Huisman (WH), C-QR Chair

WH (C-QR Chair) reported about the past and ongoing activities within the EFLM functional units. Power point presentation with the report can be viewed and downloaded from EFLM's website.

3.4. Report from the Education & Training Committee, D. Pasalic (DP), C-ET Chair

DP (C-ET Chair) reported about the past and ongoing activities within the EFLM functional units. Power point presentation with the report can be viewed and downloaded from EFLM's website.

3.5. Report from the Communication Committee, M. Graziani (MSG), C-C Chair

MSG (C-C Chair) reported about the past and ongoing activities within the EFLM functional units. Power point presentation with the report can be viewed and downloaded from EFLM's website.

4. Session 4 - Closing remarks

4.1. Date and place of next General Meeting and closing remarks, M. Neumaier, President

MN warmly thanked the audience and reminded that the next GM will take place in Barcelona, in concomitance with EuroMedLab 2019.

Meeting ended at 19.00